Cargando…
Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors
Autores principales: | Imig, John D., Morisseau, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544929/ https://www.ncbi.nlm.nih.gov/pubmed/33071800 http://dx.doi.org/10.3389/fphar.2020.598858 |
Ejemplares similares
-
Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation
por: Wagner, Karen M., et al.
Publicado: (2021) -
Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis
por: McReynolds, Cindy B., et al.
Publicado: (2019) -
Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty
Acid Amide Hydrolase Inhibitors
por: Kodani, Sean D., et al.
Publicado: (2018) -
Inhibition of Soluble Epoxide Hydrolase for Renal Health
por: Liu, Jun-Yan
Publicado: (2019) -
Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales
por: Kitamura, Seiya, et al.
Publicado: (2017)